Drug intelligence / Profile preview

Prof-002

Development stage: Preclinical
Lead developer: ProFem

Overview

Prof-002 is a preclinical-stage drug candidate under development by ProFem, an Austrian biotechnology company focused on women's health. The agent is being investigated for the treatment of bacterial vaginosis (BV). As of the current pipeline status, Prof-002 is in the preclinical or proof-of-concept (PoC) phase. Specific details regarding its chemical structure, modality, and exact mechanism of action have not been disclosed, though it follows the company's focus on addressing gynecological infections and biofilm-associated resistance mechanisms.

Beyond the preview

Go deeper on Prof-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prof-002.

Explore the full profile